TT virus (TTV) is a newly identified single-stranded DNA virus. We retrospectively analysed serum samples from sixteen patients, infected with both hepatitis C virus (HCV) and TTV, and who had been treated with interferon. An elevated serum alanine aminotransferase level after interferon was associated with persistence of HCV (abnormal in five of seven patients with persistence of HCV compared with normal in all nine patients who showed eradication of HCV) irrespective of persistence of TTV. Comparison of partial viral DNA nucleotide sequences and phylogenetic analysis showed that viral strains that had a high identity to the prototype virus were more resistant to interferon than those showing low nucleotide sequence identity. Although we observed no liver cell injury caused by persistent TTV infection, the mechanism(s) of TTV resistance to interferon should be further investigated for a better understanding of viral diseases and establishment of therapy.
TT virus (TTV) is a newly identified single-stranded DNA virus. We retrospectively analysed serum samples from sixteen patients, infected with both hepatitis C virus (HCV) and TTV, and who had been treated with interferon. An elevated serum alanine aminotransferase level after interferon was associated with persistence of HCV (abnormal in five of seven patients with persistence of HCV compared with normal in all nine patients who showed eradication of HCV) irrespective of persistence of TTV. Comparison of partial viral DNA nucleotide sequences and phylogenetic analysis showed that viral strains that had a high identity to the prototype virus were more resistant to interferon than those showing low nucleotide sequence identity. Although we observed no liver cell injury caused by persistent TTV infection, the mechanism(s) of TTV resistance to interferon should be further investigated for a better understanding of viral diseases and establishment of therapy.
TT virus (TTV) is a newly identified DNA virus isolated by representational difference analysis from patients with acute post-transfusion non-A to -G hepatitis (Nishizawa et al., 1997 ; Okamoto et al., 1998) . Although the characteristic features of the virus are not fully understood, the close association between DNA titre and alanine aminotransferase (ALT) activity suggests that TTV is the causative agent of posttransfusional hepatitis. In the initial report of Nishizawa et al. (1997) , three patients with post-transfusion hepatitis were described. Based on their description, TTV seems to cause only a mild form of liver injury. However, one of the three patients showed persistence of the virus for more then 21 weeks after blood transfusion, indicating that TTV can potentially cause a Author for correspondence : Kazuaki Chayama.
Fax j81 44 860 1356. e-mail chayama!mba.sphere.ne.jp chronic infection in humans. It is thus important to characterize the clinical course of TTV infection, including prevention and development of effective therapies.
To study liver pathogenesis and susceptibility of TTV to interferon, we retrospectively analysed pretreatment serum samples obtained from patients with chronic hepatitis C virus (HCV) infection who tested positive for serological group 2 HCV antibody (Tanaka et al., 1994) and were subsequently treated with interferon (IFN). We identified 16 TTV-positive patients and examined serial serum samples from these patients for the presence of TTV and HCV.
Virus DNA was extracted from 100 µl of serum sample by digestion with proteinase K and SDS followed by three extractions with phenol and a single chloroform extraction. The DNA was precipitated with 1n0 µg glycogen by absolute ethanol and dissolved in 20 µl H # O. Five µl of the DNA solution was subjected to PCR as described previously (Okamoto et al., 1998) . Primers used for the detection of TTV were NG059 (sense : 5h CACCAGGAGCATATACAGAC 3h) and NG063 (antisense : 5h CTGGCATTTTACCATTTCCA-AAGTT 3h) for the first PCR and NG061 (sense : 5h GGCAACATGTTATGGATAGACTGG 3h) and NG063 for the second PCR. Amplification was performed in the first PCR over 30 cycles (94 mC for 30 s ; 60 mC for 45 s ; 72 mC for 45 s) after initial denaturing at 94 mC for 4 min and a final extension at 72 mC for 7 min, and 35 cycles in the second PCR using the above time-temperature conditions. IFN therapy resulted in the eradication of TTV in seven of the sixteen patients. Persistent absence of both HCV and TTV was observed in five of the sixteen patients (Patients 1-5, Table 1 ). Patients in this group (responders) showed a complete normalization of serum ALT. Eradication of HCV only was seen in another four patients (Patients 6-9) who also showed normal ALT activity despite persistence of TTV. One patient in this group (Patient 7) showed persistence of TTV for 55 months after cessation of IFN therapy but this was not associated with elevated ALT levels. In contrast, elevation of ALT was noted in 2 patients in whom only TTV was eliminated (Patients 10 and 11) and three of the five patients in Table 1 . Serial quantitative analyses of HCV and TTV by competitive PCR Quantitative analysis was performed just before, 1 week and 2 weeks after commencement of IFN therapy, at the end of therapy and 6 months after. Each value represents the number of viruses at 10 n copies\ml of serum sample. (j) represents positive results by nested PCR but 10# copies\ml by quantification. (k) represents negative results by nested PCR. Detection of virus only, without quantification, was performed 6 months after cessation of therapy. TTV DNA was not amplified using samples obtained from Patients 3, 5, 11 and 16 using primers for quantification. , Not analysed.
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whom IFN therapy failed to eliminate both viruses (Patients 12, 15 and 16). Elevation of ALT was significantly associated with persistence of HCV (P l 0n034, Fisher's exact test) but not with TTV. This finding indicates that IFN is useful for the suppression of TTV in addition to its well-known effect on HCV (Di Bisceglie et al., 1989 ; Davis et al., 1989 ; Chayama et al., 1991) . It should be emphasized that ALT did not increase after treatment in four patients although PCR analysis showed persistence of TTV in these patients (Patients 6-9). The effect of chronic TTV infection on liver function should be carefully assessed in such patients, particularly the long-term consequences. The titres of HCV and TTV before, during and after IFN therapy were quantified by competitive PCR. Quantification of TTV DNA was done by competitive PCR as described for HCV (Chayama et al., 1993) . Briefly, a DNA fragment amplified by PCR using primers RD037 (5h GCAGCAGCATATGGA-TATGT 3h) and RD038 (5h TGACTGTGCTAAGCCTCTA 3h) (Nishizawa et al., 1997 ) from a patient positive for TTV was cloned into plasmid pUC19. A 30 bp deletion [nt 2129-2158 of TTV DNA (Okamoto et al., 1998) ] was introduced and used as an internal standard for competitive PCR. After measuring the concentration of the purified plasmid with a spectrophotometer, serial dilutions of the plasmid which contained 10"-10( copies\µl were prepared and amplified with extracted DNA samples obtained from patients. The first-round PCR was performed using RD037 and RD038 for 35 cycles (94 mC, 30 s ; 55 mC, 30 s ; and 72 mC, 45 s with an additional 7 min in the last cycle). The second-round PCR was carried out with RD051 (5h CATACACATGAATGCCAGGC 3h) and RD052 (5h GTACTTCTTGCTGGTGAAAT 3h) using the above time-temperature conditions. Competitive PCR for quantification of HCV was also performed as described previously (Chayama et al., 1993) . We were able to detect serial quantitative changes in twelve of sixteen patients (before treatment, 1 and 2 weeks after treatment and 6 months after cessation of therapy) but were unable to measure such change in the remaining four patients (Patients 3, 5, 11 and 16), probably due to mismatch of the above quantification primers.
In each patient, the pretreatment titres of HCV were higher than those of TTV (P 0n001, Mann-Whitney U-test). Titres of both viruses decreased rapidly in those patients in whom treatment resulted in eradication of both viruses. It should be noted that two (Patients 7 and 8) of the eight patients who continued to harbour TTV after IFN treatment showed a very poor reduction in TTV titre during IFN treatment although they showed a reduction in HCV titre (Table 1) . These results clearly showed a differential effect for IFN on HCV and TTV.
We further examined nucleotide sequences of TTV to see whether there is a relationship between sequence and susceptibility to IFN. Nucleotide sequences of TTV were determined using serum samples from ten of sixteen patients. For sequencing of TTV DNA, PCR products amplified primers NG061 and NG063 were used as templates. The NG061 GDC Fig. 1 . Partial nucleotide (left) and amino acid (right) sequences of TTV isolated from ten patients infected with both HCV and TTV, compared with the prototype TTV genotype 1a (TTVG1a), 1b (TTVG1b), 2a (TTV2a) and 2b (TTVG2b) sequences. Nucleotide and amino acid numbers (open reading frame 1) are those of TTV DNA reported by Okamoto et al. (1998) . Fig. 2 . Phylogenetic tree of TTV based on the nucleotide sequences shown in Fig. 1 . G1a, G1b, G2a and G2b represent the genotype 1a, 1b, 2a and 2b sequences reported by Okamoto et al. (1998) . Numbers in parentheses represent phylogenetic distance. Encircled patients represent those who became negative for TTV after IFN therapy.
primer was employed as a sequencing primer. Nucleotide and deduced amino acid sequences of ten TTV samples are shown in Fig. 1 . All ten sequences showed high identity to the prototype TTV G1a genotype (Okamoto et al., 1998) . The total numbers of synonymous and nonsynonymous substitutions among nucleotide sequences were estimated by GDD the method of Gojobori et al. (1982) . Using this number, a phylogenetic tree was constructed by the neighbour-joining method (Saitou et al., 1987) (Fig. 2) . All four patients who tested negative for TTV after IFN therapy (Patients 1, 2, 4, 10) harboured TTV strains that showed longer phylogenetic distances to prototype G1a compared with strains that persisted after IFN therapy (P l 0n038, Mann-Whitney Utest). These findings suggest that variants with multiple substitutions in the genomic sequence are likely to be more easily eliminated by IFN, although this should be further confirmed by examining isolates in a larger number of patients and belonging to different genotypes.
It should be noted that certain strains of TTV are quite resistant to IFN although IFN effectively reduced HCV in the same patients (Table 1 , Patients 7 and 8). Thus, TTV may possess certain mechanisms to evade host defence by IFN. Further studies are necessary to investigate TTV resistance to IFN therapy and to develop more effective strategies for the treatment of this viral disease.
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